Literature DB >> 34811701

A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.

Atsushi Naganuma1, Yuhei Suzuki1, Takashi Hoshino1, Hidetoshi Yasuoka1, Yuki Tamura1, Hiroaki Naruse1, Hiroshi Tanaka2, Keitaro Hirai2, Ichiro Sakamoto2, Tetsushi Ogawa2, Takeshi Hatanaka3, Satoru Kakizaki4,5.   

Abstract

We herein report a successfully treated case of huge ruptured hepatocellular carcinoma (HCC) by conversion hepatectomy after transarterial embolization (TAE) and lenvatinib therapy. A 33-year-old male patient with right hypochondralgia and liver tumor was referred to our hospital. He had a history of surgery for heart malformation. The tumor at the right lobe was 15 cm in diameter with bloody ascites. Right atrial thrombus 4.5 cm in diameter and marked cardiac dilatation were observed. TAE with ethanol suspended in lipiodol and gelatin sponge achieved hemostasis of the ruptured HCC. Although viable HCC remained after TAE, surgical treatment was abandoned because of abdominal wall invasion and his heart function. Lenvatinib and rivaroxaban were then initiated for HCC and atrial thrombus, respectively. Lenvatinib treatment resulted in a reduction in tumor marker levels and the tumor size. First, we planned conversion hepatectomy after 5 months of lenvatinib. However, recurrence of atrial thrombus prompted us to put off the surgery, and lenvatinib was re-administered. After improvement of atrial thrombus, we finally performed conversion hepatectomy 10 months after starting lenvatinib administration. The tumor was completely removed by combined resection of the diaphragm, and the patient has been doing well without any signs of recurrence.
© 2021. Japanese Society of Gastroenterology.

Entities:  

Keywords:  Conversion hepatectomy; Hepatocellular carcinoma; Lenvatinib; Transarterial embolization

Mesh:

Substances:

Year:  2021        PMID: 34811701     DOI: 10.1007/s12328-021-01558-5

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  3 in total

1.  Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.

Authors:  Sawako Uchida-Kobayashi; Ken Kageyama; Akira Yamamoto; Hiroko Ikenaga; Kanako Yoshida; Kohei Kotani; Kenjiro Kimura; Naoshi Odagiri; Atsushi Hagihara; Hideki Fujii; Masaru Enomoto; Akihiro Tamori; Shoji Kubo; Yukio Miki; Norifumi Kawada
Journal:  Oncology       Date:  2020-10-08       Impact factor: 2.935

2.  Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.

Authors:  Daiki Yamashige; Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Nozomu Muraishi; Akira Kajiwara; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Hiromitsu Kumada
Journal:  Oncology       Date:  2020-11-18       Impact factor: 2.935

3.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

  3 in total
  2 in total

1.  Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.

Authors:  Yoshifumi Hidaka; Miyo Tomita; Ryosuke Desaki; Masahiro Hamanoue; Sonshin Takao; Mari Kirishima; Takao Ohtsuka
Journal:  World J Surg Oncol       Date:  2022-07-12       Impact factor: 3.253

2.  Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

Authors:  Yoshihiko Yano; Atsushi Yamamoto; Akihiro Minami; Kenji Momose; Takuya Mimura; Soo Ki Kim; Hiroki Hayashi; Takuo Kado; Hirotaka Hirano; Seiya Hirohata; Seitetsu Yoon; Katsuhisa Nishi; Hiroshi Tei; Hidenori Tanaka; Sachiko Oouchi; Takanori Matsuura; Eiichiro Yasutomi; Yuri Hatazawa; Yuuki Shiomi; Yoshihide Ueda; Yuzo Kodama
Journal:  JGH Open       Date:  2022-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.